Physician profile
Danier Moore
NPI 1316237282
$1,935.84
in general payments reported to CMS, 2019-2025
31 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2022: $29.52 · 2023: $319 · 2024: $794 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $290.22 | 2023-2024 | Localizer, Trunode |
| Novartis Pharmaceuticals Corporation | $204.32 | 2019-2025 | |
| Janssen Biotech, INC. | $158.41 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Axogen | $155.23 | 2024 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap, Axoguard Nerve Protector |
| Astrazeneca Pharmaceuticals LP | $143.55 | 2024-2025 | Lynparza, Tagrisso, Enhertu |
| Abbvie INC. | $106.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $84.65 | 2023-2025 | Keytruda, Lynparza |
| Biocomposites INC | $83.19 | 2024-2025 | Stimulan |
| Eisai INC. | $72.12 | 2023-2024 | |
| Exelixis INC. | $63.43 | 2024-2025 | Cabometyx |
| Incyte Corporation | $57.81 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Sobi, INC | $40.08 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.99 | 2019-2025 | Alunbrig |
| Alexion Pharmaceuticals, INC. | $35.96 | 2019-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $35.65 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $32.65 | 2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $31.12 | 2023-2024 | |
| Merit Medical Systems INC | $29.52 | 2022 | |
| Impedimed, INC. | $28.72 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $28.70 | 2025 | Libtayo |
| Genmab U.S., INC. | $26.10 | 2025 | Tivdak |
| Tersera Therapeutics LLC | $24.01 | 2024 | Zoladex |
| Azurity Pharmaceuticals, INC. | $23.88 | 2025 | Danziten |
| Stemline Therapeutics INC. | $22.68 | 2024 | Orserdu |
| Aveo Pharmaceuticals, INC. | $22.49 | 2025 | |
| Beigene USA, INC. | $20.13 | 2024 | Brukinsa |
| Genentech USA, INC. | $17.72 | 2024 | Phesgo, Perjeta |
| Beone Medicines USA, INC. | $16.22 | 2025 | Brukinsa |
| Acera Surgical, INC. | $15.70 | 2023 | Restrata Wound Matrix |
| Mindray Ds USA, INC. | $14.41 | 2024 | Te X, Te7 Max |
| Taiho Oncology, INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danier Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.